Hyperthyroidism enhances endothelium-dependent relaxation in the rat renal artery

Cardiovasc Res. 2003 Jul 1;59(1):181-8. doi: 10.1016/s0008-6363(03)00326-2.

Abstract

Objective: Hyperthyroidism has pronounced effects on vascular function and endothelium-dependent relaxation. The aim of the present study was to identify mechanisms underlying hyperthyroidism-induced alterations in endothelial function in rats.

Methods: Animals were subjected to either a single injection (36 h) or 8 weeks treatment with the thyroid hormone triiodothyronine (T3, i.p.). Vascular reactivity and agonist-induced hyperpolarization were studied in isolated renal arteries. Endothelial nitric oxide (NO) synthase expression and cyclic AMP accumulation were determined in aortic segments.

Results: Endothelium-dependent relaxations to acetylcholine (ACh) were enhanced by T3 36 h after injection and after treatment for 8 weeks. Thirty-six hours after T3 application, relaxation mediated by the endothelium-derived hyperpolarizing factor (EDHF) and by endothelium-derived NO were significantly enhanced. After 8 weeks treatment with T3, however, EDHF-mediated relaxation was impaired, whereas NO-mediated relaxation remained enhanced. KCl- and ACh-induced hyperpolarizations were more pronounced in arteries from rats treated with T3 for 36 h compared to control, whereas in arteries from rats treated with T3 for 8 weeks both responses were attenuated. In rats treated for 36 h, vascular cyclic AMP levels were enhanced in the aorta and inhibition of protein kinase A attenuated EDHF-mediated relaxations of the renal artery without affecting responses in arteries from the control group. In the aorta from rats treated with T3 for 8 weeks, the expression of the endothelial NO synthase was markedly up-regulated (463+/-68%).

Conclusions: These data indicate that short-term treatment with T3 increases endothelium-dependent relaxation, most probably by increasing vascular cyclic AMP content. Following treatment with T3 for 8 weeks, expression of the endothelial NO synthase was enhanced. During this phase, NO appears to be the predominant endothelium-derived vasodilator.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Animals
  • Biological Factors / metabolism
  • Cyclic AMP / metabolism
  • Diclofenac / pharmacology
  • Endothelium, Vascular / metabolism*
  • Hyperthyroidism / metabolism*
  • In Vitro Techniques
  • Male
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase / metabolism
  • Nitric Oxide Synthase Type III
  • Potassium Chloride / pharmacology
  • Rats
  • Rats, Inbred WKY
  • Renal Artery / metabolism*
  • Triiodothyronine
  • Vasodilation*
  • Vasodilator Agents / pharmacology

Substances

  • Biological Factors
  • Vasodilator Agents
  • endothelium-dependent hyperpolarization factor
  • Triiodothyronine
  • Diclofenac
  • Nitric Oxide
  • Potassium Chloride
  • Cyclic AMP
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat
  • Acetylcholine